AstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control Rates
September 11 2023 - 2:55AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan,
a cancer drug, combined with the Imfinzi cancer treatment--with or
without chemotherapy--showed disease control rates of 92% and 93%
respectively in patients with previously untreated advanced or
metastatic non-small cell lung cancer.
The Anglo-Swedish pharma giant said Monday that the results
reinforced its confidence in this being a potential treatment
option for patients with this type of lung cancer.
"Three ongoing pivotal trials are evaluating datopotamab
deruxtecan and immune checkpoint inhibitor combinations in
first-line advanced non-small cell lung cancer," AstraZeneca
said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 11, 2023 02:40 ET (06:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Aug 2023 to Aug 2024